Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
In a retrospective study, we compared 15 patients who received cyclosporine (CsA), methotrexate (MTX) and prednisone (PDN) and 15 patients who received CsA-MTX for GVHD prophylaxis after allogeneic BMT (HLA-identical sibling (n = 22), related one HLA mismatch (n = 1), unrelated matched donors (n = 6), unrelated one HLA mismatch (n = 1)). The primary objectives of this study were to compare the incidence of GVHD and post-transplantation complications. Secondary objectives were to compare relapse rate, transplant-related mortality and overall survival. The incidence of acute GVHD grade III-IV was similar between the two groups (P = 0.66), as was the incidence of chronic GVHD (P = 0.67). Incidence of arterial hypertension was significantly higher in patients who received prophylactic PDN, (P = 0.03) and more insulin treatment was required in this group (P = 0.003). We observed no differences in the incidence of infections or upper digestive tract bleeding. Musculoskeletal complications appeared earlier in the group which received PDN. With a median follow-up of 4.4 years, patients in the CsA-MTX group had better overall survival, 46.7% vs 13.3% (P = 0.026). Relapse was a more frequent cause of death in the CsA-MTX group, whereas procedure-related mortality was more frequent in the CsA-MTX-PDN group (P = 0.013). These results suggest that prophylactic prednisone when combined with cyclosporine and methotrexate adds no benefit in acute or chronic GVHD prevention and may increase the morbidity of allogeneic transplantation. Corticosteroids may be reserved for GVHD treatment.
Ancín
I
I
Department of Clinical Hematology, Hospital Duran i Reynals, Institut Català d'Oncologia, Spain. 30.097iaa@comb.es
Ferrá
C
C
Gallardo
D
D
Peris
J
J
Berlanga
J
J
Gonzalez
J R
JR
Virgili
N
N
Grañena
A
A
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000633:toxicity; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000633:toxicity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000633:toxicity; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods* / Q000592:standards; D002423:Cause of Death; D016572:Cyclosporine / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000150:complications / Q000401:mortality / Q000628:therapy; D006801:Humans; D006973:Hypertension / Q000209:etiology; D007239:Infections / Q000209:etiology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000633:toxicity; D008875:Middle Aged; D009140:Musculoskeletal Diseases / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage / Q000633:toxicity; D012189:Retrospective Studies; D016019:Survival Analysis; D013810:Therapeutic Equivalency; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000379:methods / Q000592:standards
D000305:Adrenal Cortex Hormones; D018931:Antineoplastic Agents, Hormonal; D016572:Cyclosporine; D011241:Prednisone; D008727:Methotrexate